April 16, 2018
Entresto helped preserve kidney function in patients with chronic heart failure
Novartis has announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, which showed that…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 12, 2018
Sanofi investing €350 million for new vaccine factory in Canada
Sanofi is investing €350 million for the construction of a new vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters…
April 11, 2018
Alexion buys Wislon Therapeutics for $855 Million
Alexion has offered to buy shares in a Stockholm-based biopharmaceutical company Wilson Therapeutics, which develops novel therapies for patients with…
April 9, 2018
Swiss drugmaker Novartis buys US-based gene therapy company for $8.7 billion
Novartis’s acquisition of the US-based Nasdaq-listed clinical stage gene therapy company AveXis for $218 per share, for total of 8.7…
April 6, 2018
Encapsulated cell therapies for the potential treatment of type 1 diabetes from Lilly and Sigilon
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for the potential treatment of…
April 5, 2018
Nordic Nanovector’s CEO steps down
Nordic Nanovector’s Chief Executive Officer Luigi Costa will step down, and the company will search for a new CEO immediately,…
April 4, 2018
Phase 3 study in second-line liver cancer patients met overall survival endpoint
Eli Lilly has announced top-line results from its Phase 3 REACH-2 study of its second-line treatment for liver cancer CYRAMZA,…
April 3, 2018
Edinburgh-based pharmaceutical company Neurocentrx aims global market with new board members
Neurocentrx, an Edinburgh-based pharmaceutical company, has appointed Nigel Brooksby as Non-Executive Chairman and Dr. Tim Corn as Non-Executive Director as…
March 29, 2018
Shire reaches regulatory milestones for investigational hereditary angioedema (HAE) treatment Lanadelumab
European Medicines Agency (EMA) has validated Shire’s marketing authorization application (MAA) for its lanadelumab, which was also accepted by Health…
March 29, 2018
EMA to review Sanofi’s potential treatment for type 1 diabetes
The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for oral treatment sotagliflozin, developed in partnership with…